摘要
Objective: To analyze the influence factors to recurrence of hepatocellular carcinoma (HHC) after its resection according to pathologic findings of the resected primary tumor and angiographic features of the recurrence tumor. Methods: In this series, 142 cases with recurrence HCC were analyzed with respect to (1) size, number, gross and histologic findings of the primary tumor; (2) time when recurrence occurred; (3) size, number, blood supply, staining property, and accumulation of lipiodol oil in the recurrence tumor. Following angiography, arterial chemoembolization was performed. Results: In 101 of the 142 (71.1%) cases, the primary tumor was>5 cm in diameter, and in 41 cases (28.9%) it was <5 cm. In 67.7% of the cases, the capsule of the primary tumor was incomplete or absent. In 67.7% of the cases, the capsule of the primary tumor was incomplete or absent. In 47 cases (33.1%), satellite tumor nodules were seen during operation but they were seen on pathologic sections in 94 cases (66.2%). Tumor thrombus was present in the portal vein in 26 cases (18.3%) during operation and 121 cases (85.2%) on pathologic examination, respectively. In the majority of the cases (99/142), recurrence had occurred within 6 months after operation. The recurrence foci consisted of multiple tumor nodules of <5 cm in 68.3% of the cases. On angiography, the recurrence tumors were rich in blood supply and with good accumulation of lipiodol after embolization. Conclusion: Recurrence is apt to occur in HCC patients with large (>5 cm) primary tumor which has incomplete or no capsule, with satellite tumor nodules and protal vein tumor thrombus. It is suggested to perform angiography 1–2 months after surgery to detect early recurrrence and, if confirmed, the patients may be treated by trans-catheter arterial chemoembolization.
Objective: To analyze the influence factors to recurrence of hepatocellular carcinoma (HHC) after its resection according to pathologic findings of the resected primary tumor and angiographic features of the recurrence tumor. Methods: In this series, 142 cases with recurrence HCC were analyzed with respect to (1) size, number, gross and histologic findings of the primary tumor; (2) time when recurrence occurred; (3) size, number, blood supply, staining property, and accumulation of lipiodol oil in the recurrence tumor. Following angiography, arterial chemoembolization was performed. Results: In 101 of the 142 (71.1%) cases, the primary tumor was>5 cm in diameter, and in 41 cases (28.9%) it was <5 cm. In 67.7% of the cases, the capsule of the primary tumor was incomplete or absent. In 67.7% of the cases, the capsule of the primary tumor was incomplete or absent. In 47 cases (33.1%), satellite tumor nodules were seen during operation but they were seen on pathologic sections in 94 cases (66.2%). Tumor thrombus was present in the portal vein in 26 cases (18.3%) during operation and 121 cases (85.2%) on pathologic examination, respectively. In the majority of the cases (99/142), recurrence had occurred within 6 months after operation. The recurrence foci consisted of multiple tumor nodules of <5 cm in 68.3% of the cases. On angiography, the recurrence tumors were rich in blood supply and with good accumulation of lipiodol after embolization. Conclusion: Recurrence is apt to occur in HCC patients with large (>5 cm) primary tumor which has incomplete or no capsule, with satellite tumor nodules and protal vein tumor thrombus. It is suggested to perform angiography 1–2 months after surgery to detect early recurrrence and, if confirmed, the patients may be treated by trans-catheter arterial chemoembolization.
